Therapeutic management of pyoderma gangrenosum.

Pyoderma gangrenosum (PG) is a primarily noninfectious inflammatory skin disease resulting in large ulcers that can spread rapidly showing undermined violaceous borders and a necrotic, purulent base. PG was first described in the 19th and early 20th centuries (1,2). Similar to Sweet’s syndrome, PG belongs to the dermatoses, which are histologically characterized by an accumulation of neutrophils without any discernible microbial pathogens. PG often develops after minor trauma, which is consistent with the phenomenon of Koebnerization, but it also occurs without a preceding injury (3–5). Owing to its numerous links to rheumatic diseases, communityand hospital-based rheumatologists are consulted regularly regarding differential diagnosis, long-term prognosis, and current treatment options. Although few controlled trials have been performed, in recent years a body of data has been accumulated from case reports and small studies including novel treatment options; this body of data has widened the therapeutic armamentarium considerably and will be discussed in detail in this review.

[1]  T. Srikrishnan,et al.  Crystal structure of methyl-3, 4-O-ethylidene-β-L- arabinopyranoside , 2003 .

[2]  M. Regueiro,et al.  Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease , 2003, American Journal of Gastroenterology.

[3]  D. Jih,et al.  Bromoderma after excessive ingestion of Ruby Red Squirt. , 2003, The New England journal of medicine.

[4]  N. Silverberg,et al.  Resolution of Pyoderma gangrenosum after Therapy with Lyophilized Bovine Collagen Matrix , 2003, Dermatology.

[5]  C. Magro,et al.  Cutaneous vasculitis: a review , 2003, Journal of cutaneous pathology.

[6]  R. Parslew,et al.  Superficial granulomatous pyoderma treated with intravenous immunoglobulin. , 2003, Journal of the American Academy of Dermatology.

[7]  C. Magro,et al.  Pyoderma gangrenosum: a review , 2003, Journal of cutaneous pathology.

[8]  D. Cornblath,et al.  Thalidomide-induced neuropathy , 2002, Neurology.

[9]  G. Stinco,et al.  Pyoderma gangrenosum of the scalp treated with cyclosporine A , 2002, International journal of dermatology.

[10]  P. R. Dahl,et al.  Skin ulcers misdiagnosed as pyoderma gangrenosum. , 2002, The New England journal of medicine.

[11]  M. Slevin,et al.  Angiogenic Oligosaccharides of Hyaluronan Induce Multiple Signaling Pathways Affecting Vascular Endothelial Cell Mitogenic and Wound Healing Responses* , 2002, The Journal of Biological Chemistry.

[12]  T. Bieber,et al.  Topical Treatment of Pyoderma gangraenosum , 2002, Dermatology.

[13]  F. Grange,et al.  Corticosteroid-Resistant Pyoderma gangrenosum Associated with Crohn’s Disease: Rapid Cure with Infliximab , 2002, Dermatology.

[14]  J. Ring,et al.  Topical platelet‐derived growth factor accelerates healing of myelodysplastic syndrome‐associated pyoderma gangrenosum , 2002, The British journal of dermatology.

[15]  J. Marks,et al.  Occupationally induced pyoderma gangrenosum. , 2002, Journal of American Academy of Dermatology.

[16]  A. Gupta,et al.  Tacrolimus: a review of its use for the management of dermatoses , 2002, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  P. Rosina,et al.  Pathergic pyoderma gangrenosum in a venous ulcer , 2002, International journal of dermatology.

[18]  H. Schöfer,et al.  Successful treatment of postoperative pyoderma gangrenosum with cyclosporin , 2002, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  J. J. Mora,et al.  Pyoderma gangrenosum associated with Wegener's granulomatosis: partial response to mycophenolate mofetil. , 2002, Rheumatology.

[20]  M. Mokni,et al.  Pyoderma gangrenosum: a report of 21 cases , 2002, International journal of dermatology.

[21]  M. Vatn,et al.  Pyoderma Gangrenosum Associated with Crohn Disease: Effect of TNF- α Blockade with Infliximab , 2002, Scandinavian journal of gastroenterology.

[22]  J. Triantafillidis,et al.  Favorable Response to Infliximab Treatment in a Patient with Active Crohn Disease and Pyoderma Gangrenosum , 2002, Scandinavian journal of gastroenterology.

[23]  U. Wollina.  Clinical Management of Pyoderma Gangrenosum , 2002, American journal of clinical dermatology.

[24]  F. Corsi,et al.  Low molecular weight hyaluronic acid prevents oxygen free radical damage to granulation tissue during wound healing. , 2002, International journal of tissue reactions.

[25]  A. Khachemoune,et al.  Diagnosis Of Leg Ulcers , 2001 .

[26]  S. Khandpur,et al.  Pyoderma Gangrenosum in Two Siblings: A Familial Predisposition , 2001, Pediatric dermatology.

[27]  M. Lebwohl,et al.  Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. , 2001, Archives of dermatology.

[28]  M. A. Chastain.  The Glucagonoma Syndrome: A Review of its Features and Discussion of New Perspectives , 2001, The American journal of the medical sciences.

[29]  M. Hoffman.  Pyoderma gangrenosum associated with c‐ANCA (h‐lamp‐2) , 2001, International journal of dermatology.

[30]  D. Stewart,et al.  Severe recalcitrant pyoderma gangrenosum responding to a combination of mycophenolate mofetil with cyclosporin and complicated by a mononeuritis , 2001, The British journal of dermatology.

[31]  K. Bower,et al.  Effective Steroid-sparing Treatment for Peripheral Ulcerative Keratitis and Pyoderma Gangrenosum , 2001, Cornea.

[32]  S. Chimenti,et al.  The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum , 2001, The Journal of dermatological treatment.

[33]  V. Falanga,et al.  Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. , 2001, Journal of the American Academy of Dermatology.

[34]  T. Werfel,et al.  Pyoderma gangraenosum Erfolgreiche topische Therapie mit Tacrolimus (FK506) , 2001, Der Hautarzt.

[35]  A. Benvenisty,et al.  Surgical management of pyoderma gangrenosum: case report and review. , 2000, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[36]  J. Callen,et al.  Clinical features and treatment of peristomal pyoderma gangrenosum. , 2000, JAMA.

[37]  P. von den Driesch,et al.  Pyoderma gangrenosum in a patient with autoimmune haemolytic anaemia and complement deficiency , 2000, The British journal of dermatology.

[38]  W. Hartschuh,et al.  Darstellung des Pyoderma gangraenosum in einem dermatologischen Atlas des frühen 19. Jahrhunderts , 2000, Der Hautarzt.

[39]  U. Wollina,et al.  Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix , 2000, Journal of the European Academy of Dermatology and Venereology : JEADV.

[40]  R. Kozarek,et al.  Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. , 2000, Archives of surgery.

[41]  C. Berking,et al.  Interleukin-8 Overexpression Is Present in Pyoderma Gangrenosum Ulcers and Leads to Ulcer Formation in Human Skin Xenografts , 2000, Laboratory Investigation.

[42]  P. Jacobs,et al.  Hyperbaric Oxygen as the Only Effective Treatment in Mutilating and Resistant Systemic Vasculitis , 2000, Hematology.

[43]  A. Fleischer,et al.  Pyoderma Gangrenosum A Comparison of Typical and Atypical Forms with an Emphasis on Time to Remission. Case Review of 86 Patients from 2 Institutions , 2000, Medicine.

[44]  R. Stadler,et al.  Posttraumatisches Pyoderma gangraenosum: Kombinationstherapie mit intravenösen Immunglobulinen und systemischen Kortikosteroiden , 1999, Der Hautarzt.

[45]  A. Simpson,et al.  Pyoderma gangrenosum - A diagnosis not to be missed , 1999 .

[46]  D. Mass,et al.  Pyoderma gangrenosum mimicking postoperative infection in the extremities. A report of two cases. , 1999, The Journal of bone and joint surgery. American volume.

[47]  M. Landthaler,et al.  Therapieresistentes Pyoderma gangraenosum Eine Behandlung mit Mycophenolatmofetil und Cyclosporin A , 1999, Der Hautarzt.

[48]  R. Marsden,et al.  Split skin grafts in the treatment of pyoderma gangrenosum. A report of four cases. , 1999, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[49]  D. Leffell,et al.  Use of a lyophilized bovine collagen matrix in postoperative wound healing. , 1999, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[50]  Jolles,et al.  Combination oral and topical tacrolimus in therapy‐resistant pyoderma gangrenosum , 1999, The British journal of dermatology.

[51]  Griffiths,et al.  Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus , 1999, The British journal of dermatology.

[52]  Hollmén,et al.  Plasmapheresis and cyclophosphamide as successful treatments for pyoderma gangrenosum , 1999, Clinical and experimental dermatology.

[53]  M. Petri,et al.  The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. , 1998, Archives of dermatology.

[54]  Arase,et al.  Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone , 1998, The British journal of dermatology.

[55]  M. Lebwohl,et al.  Recalcitrant pyoderma gangrenosum: treatment with thalidomide. , 1998, Journal of the American Academy of Dermatology.

[56]  S. Burge,et al.  Lesson of the week: Early diagnosis of pyoderma gangrenosum is important to prevent disfigurement , 1998, BMJ.

[57]  J. Callen,et al.  Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. , 1996, Journal of the American Academy of Dermatology.

[58]  V. Ho,et al.  Treatment of pyoderma gangrenosum. , 1996, Journal of the American Academy of Dermatology.

[59]  W. Su,et al.  Pyoderma gangrenosum: classification and management. , 1996, Journal of the American Academy of Dermatology.

[60]  G. Krasznai,et al.  [Ulcerative colitis associated with pyoderma gangrenosum]. , 1994, Orvosi hetilap.

[61]  C. Sanders,et al.  Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. , 1993, Cutis.

[62]  J. H. Haseman,et al.  The evolution of pyoderma gangrenosum. A clinicopathologic correlation. , 1993, The American Journal of dermatopathology.

[63]  O. J. Stone.  Sulfapyridine and sulfones decrease glycosaminoglycans viscosity in dermatitis herpetiformis, ulcerative colitis, and pyoderma gangrenosum. , 1990, Medical hypotheses.

[64]  N. Reynolds,et al.  Response of atypical bullous pyoderma gangrenosum to oral minocycline hydrochloride and topical steroids. , 1990, Acta dermato-venereologica.

[65]  J. Callen,et al.  Chlorambucil--an effective corticosteroid-sparing therapy for pyoderma gangrenosum. , 1989, Journal of the American Academy of Dermatology.

[66]  H. Mensing.  Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum). Open clinical trial. , 1988, Dermatologica.

[67]  D. Jc,et al.  Pyoderma gangrenosum: skin grafting after preparation with hyperbaric oxygen. , 1987 .

[68]  W. Su,et al.  Histopathologic and immunopathologic study of pyoderma gangrenosum , 1986, Journal of cutaneous pathology.

[69]  Venencie Py,et al.  [Pyoderma gangrenosum in a child. Treatment with thalidomide (author's transl)]. , 1982 .

[70]  B. Davis,et al.  Pyoderma gangrenosum treated with clofazimine. Report of three cases. , 1981, Journal of the American Academy of Dermatology.

[71]  K. Thomsen,et al.  Clofazimine in the treatment of pyoderma gangrenosum. , 1979, Archives of dermatology.

[72]  M. Weber,et al.  [Pyoderma gangrenosum: Clofazimine therapy]. , 1977, Annales de dermatologie et de venereologie.

[73]  L. Brunsting,et al.  PYODERMA (ECHTHYMA) GANGRENOSUM: CLINICAL AND EXPERIMENTAL OBSERVATIONS IN FIVE CASES OCCURRING IN ADULTS , 1930 .